• Title/Summary/Keyword: ASCO

Search Result 19, Processing Time 0.037 seconds

Interfacial Properties of Propylene Oxide Adducted Sodium Laureth Sulfate Anionic Surfactant (프로필렌 옥사이드를 부가한 소듐 라우레스 설페이트 음이온 계면활성제의 계면 특성에 관한 연구)

  • Jeong Min Lee;Ki Ho Park;Hee Dong Shin;Woo Jin Jeong;Jong Choo Lim
    • Applied Chemistry for Engineering
    • /
    • v.34 no.3
    • /
    • pp.264-271
    • /
    • 2023
  • In this study, ASCO SLES-430 surfactant was synthesized by adducting 3 moles of ethylene oxide and 1 mole of propylene oxide to lauryl alcohol followed by a sulfation process, and the structure of the synthesized ASCO SLES-430 was elucidated by performing FT-IR, 1H-NMR and 13C-NMR analyses. Interfacial properties such as critical micelle concentration, static surface tension, emulsification index, and contact angle were measured, and environmental compatibility indices such as oral toxicity and skin irritation were also estimated for ASCO SLES-430. Both results were compared with ASCO SLES-226 and ASCO SLES-328 SLES surfactants possessing 2 moles and 3 moles of ethylene oxide, respectively. In particular, both foaming ability and foam stability were evaluated for ASCO SLES-430 and compared with ASCO SLES-226 and ASCO SLES-328, which have been widely used in detergent products, in order to test the potential applicability of ASCO SLES-430 in detergent product formulation for a small capacity built-in washing machine.

Acute Oral and Genetic Toxicity Study of ASCO EAQ80, a Novel Cationic Surfactant (투명 양이온 계면활성제 ASCO EAQ80에 대한 급성 경구 독성시험 및 유전 독성시험에 관한 연구)

  • Kim, Byeong-Jo;Kim, Dong-Hyeon;Lee, Jong-Ki;Moon, Surk-Sik
    • Applied Chemistry for Engineering
    • /
    • v.20 no.2
    • /
    • pp.145-153
    • /
    • 2009
  • The acute oral and genetic toxicity of ASCO EAQ80 was established in this study. ASCO EAQ80, a novel cationic surfactant produced by Aekyung Speciality Chemicals Co. LTD. is currently commercialized as a clear fabric softener. In acute oral toxicity study, the 50% lethal dose $(LD_{50})$ of ASCO EAQ80 was determined to be higher than 5000 mg/kg and this product could be classified as Category 5 or Unclassified by Globally Harmonized Classification System. Also, to establish the gene-toxicity of ASCO EAQ80, we performed bacterial reversion assay against Salmonella typhimurium TA98, TA100, TA1535, TA1537, Escherichia coli WP2uvrA, and in vitro chromosomal aberration assay against Chinese hamster lung cells in the presence and absence of S-9 metabolic activation system. From these experiments, ASCO EAQ80 revealed nonmutagenic potential in S. typhimurium TA98, TA100, TA1535, TA1537, and Escherichia coli WP2uvrA both in the absence and presence of metabolic activation system. No clastogenicity of ASCO EAQ80 was observed in chromosomal aberration assay in vitro.

Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (2019 미국 임상종양학회 두경부암 하이라이트)

  • Lee, Yun-Gyoo
    • Korean Journal of Head & Neck Oncology
    • /
    • v.35 no.2
    • /
    • pp.1-10
    • /
    • 2019
  • The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31-June 4 in Chicago, drew more than 32,000 oncology specialists from around the world. The theme of 2019 ASCO conference was "Caring for Every Patient, Learning from Every Patient". Among the topics of interest covered were new approaches to surmount limited access to cancer care and the latest advances in targeted therapies for pancreatic, prostate cancers and soft tissue sarcomas. In the field of head and neck cancer, 8 oral abstracts and 75 poster abstracts were presented at this meeting. In this review, we are going to summarize the eight studies that have been presented orally. The topics are recurrent and/or metastatic head and neck squamous cell carcinoma for two abstracts (#6000, #6002), salivary duct carcinoma for one abstract (#6001), locally advanced nasopharyngeal carcinoma for two abstracts (#6003, #6004), oropharyngeal carcinoma for two abstracts (#6006, #6008), and oral cavity cancer for one abstract (#6007).

Effect of pH on Physical Properties of Triethanolamine-Ester Quaternary Ammonium Salt Cationic Surfactant System (수용액의 pH가 Triethanolamine-Ester Quaternary Ammonium Salt 양이온 계면활성제 시스템의 물성에 미치는 영향에 관한 연구)

  • Kim, JiSung;Lim, JongChoo
    • Applied Chemistry for Engineering
    • /
    • v.20 no.5
    • /
    • pp.479-485
    • /
    • 2009
  • In this study, basic physical properties were measured for ASCO EQ85 cationic surfactant of triethanolamine-ester quaternary ammonium salt and effect of pH on softening performance on fabrics was investigated using zeta potential measurement and adsorption experiment by quartz crystal microbalance. The CMC of the surfactant was near $3{\times}10^{-3}mol/L$ and the surface tension at CMC was about 40 mN/m. The interfacial tension measurement between 1 wt% aqueous solution and n-dodecane measured by spinning drop tensiometer showed that interfacial tension slightly increased with an increase in pH but the equilibration time was not affected by pH. The surfactant adsorption was found to increase with an increase in surfactant concentration and was also affected by pH of surfactant solution. The friction factor for fabrics treated with ASCO EQ85 surfactant was shown to increase with pH and better softening effect was found under acidic conditions. Half-life for foams generated with ASCO EQ85 surfactant solution increased with pH, which indicated an increase in foam stability with pH.

Numerical Analysis of Smoke Control for high-rise Building Considering with the Enthalpy Equation (Enthalpy Equation을 이용한 고층 건물의 제연해석)

  • Bae, Sung-Ryong;Ro, Kyoung-Chul;Ko, Gwon-Hyun;Ryou, Hong-Sun
    • Fire Science and Engineering
    • /
    • v.24 no.4
    • /
    • pp.27-32
    • /
    • 2010
  • Recently, increases of population density due to the industrialization in the metropolitan cities has caused the high-density and integration of life environment. Then various high-rise buildings are constructed for accommodation. However, high-rise building fires can cause high casualties due to increases of smoke spread velocity through the vertical shaft. In this study, the new program based on the enthalpy conservation for analysis of energy transfer for smoke control system, CAU_ESCAP, was developed. CAU_ESCAP was validated by comparing with the result of ASCOS. The characteristic of smoke control was analysed by using CAU_ESCAP for high-rise building fires.

Prevalence of HER-2-Positive Invasive Breast Cancer: A Systematic Review from Iran

  • Keyhani, Elahe;Muhammadnejad, Ahad;Karimlou, Masoud
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.11
    • /
    • pp.5477-5482
    • /
    • 2012
  • Background: The HER-2/neu gene is altered in 15-20% of breast cancer patients. Immunohistochemistry (IHC) is considered to be the most cost-effective method for HER-2 detection in many countries. Approximately 8,000 new cases of breast cancer are observed annually in Iran. The aims of this study were to conduct a systematic review of the literature on the rate of HER-2-positive breast cancer diagnosed by IHC in Iran. Methods: A systematic search of the medical literature using the Medline/PubMed, ISI and SID databases revealed articles published in the English and Persian languages evaluating HER-2-positive breast cancer in Iran. Results: From 22 studies, 3,033 patients were evaluated, of whom 1,350 were diagnosed as HER-2-positive by IHC HER-2 testing. The mean percentage of HER-2-positive patients was 44.5%, which is higher than that recorded in international statistics. Results of this meta-analysis showed a significant heterogeneity between ratios. There was a statistically significant difference between the results of pre- and post implementation of 2007 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline. IHC HER-2 testing has been performed in Iran for over 10 years. Similar to many other countries, before establishment of an infrastructure for IHC diagnostic tests, HER-2 testing was routinely performed in Iran. Our study showed that the statistics reported from Iran varied widely; for instance, the rate of HER-2-positive cases varied from 23.3% to 81.0%. Conclusions: Our results demonstrate that the lack of standardization and harmonization of this test have led to marked variations in breast cancer diagnosis in Iran.

Neoadjuvant Chemotherapy for Resectable Esophageal Carcinoma: A Meta-analysis of Randomized Clinical Trials

  • Xu, Xiao-Hua;Peng, Xue-Hong;Yu, Ping;Xu, Xiao-Yuan;Cai, Er-Hui;Guo, Pi;Li, Ke
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.1
    • /
    • pp.103-110
    • /
    • 2012
  • Neoadjuvant chemotherapy for resectable esophageal carcinoma has been a focus of study, but no agreement has been reached on clinical randomized controlled trials and relevant systematic evaluation. The purpose of this study was to perform a meta-analysis on published randomized controlled trials (RCTs) that compared neoadjuvant chemotherapy and surgery with surgery alone for resectable esophageal carcinoma. Medline and manual searches was conducted in PubMed, ASCO (American Society of Clinical Oncology) meeting summary, Embase, the Cochrane Library (up to October 2010), Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Database, Wanfang Database. The selection contents were to identify all published and unpublished RCTs that compared neoadjuvant chemotherapy and surgery with surgery alone for resectable esophageal carcinoma. Sixteen RCTs which included 2,594 patients were selected. The risk ratio (RR) (95% confidence interval [CI]; P value), expressed as neoadjuvant chemotherapy and surgery versus surgery alone (treatment versus control), was 1.02 (0.95, 1.10; P=0.54) for 1-year survival, 1.29 (1.13, 1.47; P=0.0001) for 3-year survival, 1.31 (1.13, 1.51; P=0.0003) for 5-year survival, 1.00 (0.95, 1.04; P= 0.85) for rate of resection and 0.89 (0.64, 1.23; P=0.48) for operative mortality. The results showed that neoadjuvant chemotherapy for resectable esophageal carcinoma can raise the overall survival rate of patients with esophageal carcinoma, but it does not affect treatment-related mortality.

Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results - a Study from Iran

  • Mehrazma, Mitra;Kalantari, Elham;Rezvani, Hamid;Bahar, Babak;Basi, Ali;Razavi, Seyed Mohsen;Rakhshani, Nasser
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.17
    • /
    • pp.7695-7700
    • /
    • 2015
  • Background: HER2/neu overexpression on cell membranes of breast cancer cells is due to HER2/neu gene amplification and it is important to identify potential candidates for anti HER2 therapy with trastuzumab. IHC, FISH and CISH are standard FDA approved assays currently used to determine HER2 status in routine practice. The aim of this study was to determine HER2 gene amplification, using the CISH method in breast carcinoma samples which had IHC +2 reactions. Materials and Methods: This study was conducted from 2008-2010 using 334 consecutive breast carcinoma samples referred from local laboratories to Mehr Hospital. CISH assays were performed for all cases, and IHC tests were also done for determining efficacy and accuracy of local labs. HER2 status in local IHC tests was compared with central IHC and CISH results. Results: Of 334 breast cancer patients, 16 were negative for HER2 IHC (0, +1), 201 cases were equivocal (+2), and 31 positive (+3). Of 334 referral cases, 88 were CISH positive (26.3%) and 246 were CISH negative (73.7%). Of 201 IHC +2 cases, HER2 gene amplification was observed in 42 cases (kappa: 0.42). A 29.9% concordance was found between local IHC and central IHC. Sensitivity and specificity of local IHC were 90% and 53.8%, respectively. Conclusions: Low accuracy of IHC results in local labs was associated with the following factors: using former FDA-approved criteria for HER2 interpretation, utilizing non-validated kits, and lack of any quality assurance program. Therefore, following the new 2014 ASCO/CAP guideline and comprehensive quality assurance should be implemented to ensure accuracy of HER2 testing.

Whole Brain Radiotherapy Plus Chemotherapy in the Treatment of Brain Metastases from Lung Cancer: A Meta-analysis of 19 Randomized Controlled Trails

  • Liu, Wen-Jing;Zeng, Xian-Tao;Qin, Hai-Feng;Gao, Hong-Jun;Bi, Wei-Jing;Liu, Xiao-Qing
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.7
    • /
    • pp.3253-3258
    • /
    • 2012
  • Objective: To evaluate the efficacy and safety of whole brain radiotherapy (WBRT) plus chemotherapy versus WBRT alone for treating brain metastases (BM) from lung cancer by performing a meta-analysis based on randomized controlled trials (RCTs). Methods: The PubMed, Embase, CENTRAL, ASCO, ESMO, CBM, CNKI, and VIP databases were searched for relevant RCTs performed between January 2000 and March 2012. After quality assessment and data extraction, the meta-analysis was performed using the RevMan 5.1 software, with funnel plot evaluation of publication bias. Results: 19 RCTs involving 1,343 patients were included. The meta-analyses demonstrated that compared to WBRT alone, WBRT plus chemotherapy was more effective with regard to the objective response rate (OR = 2.30, 95% CI = 1.79 - 2.98; P < 0.001); however, the incidences of gastrointestinal reactions (RR = 3.82, 95% CI = 2.33 - 6.28, P <0.001), bone marrow suppression (RR = 5.49, 95% CI = 3.65 - 8.25, P < 0.001), thrombocytopenia (RR = 5.83, 95% CI = 0.39 - 86.59; P = 0.20), leukopenia (RR = 3.13, 95% CI = 1.77 - 5.51; P < 0.001), and neutropenia (RR = 2.75, 95% CI = 1.61 - 4.68; P < 0.001) in patients treated with WBRT plus chemotherapy were higher than with WBRT alone. There was no obvious publication bias detected. Conclusion: WBRT plus chemotherapy can obviously improve total efficacy rate, butalso increases the incidence of adverse reactions compared to WBRT alone. From the limitations of this study, more large-scale, high-quality RCTs are suggested for further verification.